Personalizing HER2-Targeted Therapy in Metastatic Breast Cancer Beyond HER2 Status: What We Have Learned from Clinical Specimens

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 7, Iss. 4, 2009-12 ,pp. : 263-274

Bentham Science Publishers

Access to resources Recommend Favorite

Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer

By  

Current Cancer Drug Targets, Vol. 9, Iss. 2, 2009-03 ,pp. : 148-162

Bentham Science Publishers

Access to resources Recommend Favorite

Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer

By Gullo Giuseppe   Bettio Daniela   Torri Valter   Masci Giovanna   Salvini Piermario   Santoro Armando  

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 179-183

Springer Publishing Company

Access to resources Recommend Favorite

In vitro evaluation and biodistribution of HER2-targeted liposomes loaded with an ¹²⁵I-labelled DNA-intercalator

By Fondell A.   Edwards K.   Unga J.   Kullberg E.   Park J. W.   Gedda L.  

Journal of Drug Targeting, Vol. 19, Iss. 9, 2011-11 ,pp. : 846-855

Informa Healthcare

Access to resources Recommend Favorite

HER2/neu (E75) vaccine reduces breast cancer recurrence

By  

Inpharma, Vol. 1, Iss. 1512, 2005-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite